Macrophage activation syndrome in autoimmune disease

International Archives of Allergy and Immunology

Volumn 153, Issue 2, 2010, Pages 109-120

  Deane, Sean ^a   Selmi, Carlo ^b   Teuber, Suzanne S ^a   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoimmune responses; Autoimmunity; Hemophagocytic syndromes; Juvenile idiopathic arthritis; Lymphohistiocytosis; Macrophage activation syndrome; Macrophages

Indexed keywords

ACETYLSALICYLIC ACID; ETANERCEPT; GOLD SALT; INFLIXIMAB; LIPID; METHOTREXATE; MORNIFLUMATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; VANCOMYCIN;

AUTOIMMUNE DISEASE; BLOOD CLOTTING DISORDER; CYTOPENIA; DISEASE ASSOCIATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; INFECTIOUS COMPLICATION; MACROPHAGE ACTIVATION SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNDROME DELINEATION; CD8+ T LYMPHOCYTE; IMMUNOLOGY; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; RHEUMATIC DISEASE;

AUTOIMMUNE DISEASES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; KILLER CELLS, NATURAL; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; RHEUMATIC DISEASES;

EID: 77950939305     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312628     Document Type: Review

References (151)

1. Hadchouel M, Prieur AM, Griscelli C: Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985; 106: 561-566.
2. Ramanan AV, Schneider R: Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 2003; 30: 401-403.
3. Ramanan AV, Schneider R: Macrophage activation syndrome - what's in a name! J Rheumatol 2003; 30: 2513-2516.
4. Filipovich AH: Hemophagocytic lymphohistiocytosis and related disorders. Curr Opin Allergy Clin Immunol 2006; 6: 410-415.
5. Henter JI: Treatment protocol for hemophagocytic lymphohistiocytosis 2004. Stockholm, National Institutes of Health, 2009.
6. Albert A, Azgui Z, Buisine J, Ciaudo M, Fenneteau O, Fillola G, Lasserre M, Merle-Beral H, Mielot F, Raphael M: Macrophage activation syndromes. Nouv Rev Fr Hematol 1992; 34: 435-441.
7. Stephan JL, Donadieu J, Ledeist F, Blanche S, Griscelli C, Fischer A: Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood 1993; 82: 2319-2323.
8. Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM: Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993; 11: 451-456.
9. Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I, Gershwin ME, Shoenfeld Y: Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 2009; 33: 178-182.
10. Blank M, Gershwin ME: Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 2008; 30: 1-4.
11. Athreya BH: Is macrophage activation syndrome a new entity? Clin Exp Rheumatol 2002; 20: 121-123.
12. Emmenegger U, Schaer DJ, Larroche C, Neftel KA: Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 2005; 135: 299-314.
13. Ramanan AV, Baildam EM: Macrophage activation syndrome is hemophagocytic lymphohistiocytosis - need for the right terminology. J Rheumatol 2002; 29: 1105, author reply 1105.
14. Behrens EM: Macrophage activation syndrome in rheumatic disease: what is the role of the antigen presenting cell? Autoimmun Rev 2008; 7: 305-308.
15. Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, Ayala R, Groh B, Finkel TH, Cron RQ: Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol 2008; 35: 343-348.
16. Janka GE: Hemophagocytic syndromes. Blood Rev 2007; 21: 245-253.
17. Janka GE: Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007; 166: 95-109.
18. Grom AA: Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities? Curr Opin Rheumatol 2003; 15: 587-590.
19. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A: Natural killer cell dysfunction in patients with systemiconset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292-296.
20. Pringe A, Trail L, Ruperto N, Buoncompagni A, Loy A, Breda L, Martini A, Ravelli A: Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication? Lupus 2007; 16: 587-592.
21. Berkun Y, Padeh S: Macrophage activation syndrome in juvenile idiopathic arthritis; in Shoenfeld Y, Cervera R, Gershwin ME (eds): Diagnostic Criteria in Autoimmune Diseases. Totowa, Humana Press, 2008, pp 21-24.
22. Recalcati S, Invernizzi P, Arosio P, Cairo G: New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun 2008; 30: 84-89.
23. Kelly A, Ramanan AV: Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol 2007; 19: 477-481.
24. Behrens EM, Beukelman T, Paessler M, Cron RQ: Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 1133-1138.
25. Schaer DJ, Schaer CA, Schoedon G, Imhof A, Kurrer MO: Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haematol 2006; 77: 432-436.
26. Stabile A, Bertoni B, Ansuini V, La Torraca I, Salli A, Rigante D: The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age. Eur Rev Med Pharmacol Sci 2006; 10: 53-59.
27. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, Viola S, Martini A: Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005; 146: 598-604.
28. Cooper GS, Bynum ML, Somers EC: Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009; 33: 197-207.
29. Hudson M, Rojas-Villarraga A, Coral-Alvarado P, Lopez-Guzman S, Mantilla RD, Chalem P, Baron M, Anaya JM: Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008; 31: 156-159.
30. Neuhausen SL, Steele L, Ryan S, Mousavi M, Pinto M, Osann KE, Flodman P, Zone JJ: Cooccurrence of celiac disease and other autoimmune diseases in celiacs and their firstdegree relatives. J Autoimmun 2008; 31: 160-165.
31. Sawhney S, Woo P, Murray KJ: Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Arch Dis Child 2001; 85: 421-426.
32. Durai M, Huang MN, Moudgil KD: Self heat-shock protein 65-mediated regulation of autoimmune arthritis. J Autoimmun 2009; 33: 208-213.
33. Emmenegger U, Reimers A, Frey U, Fux C, Bihl F, Semela D, Cottagnoud P, Cerny A, Spaeth PJ, Neftel KA: Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly 2002; 132: 230-236.
34. Scott RB, Robb-Smith AHB: Histiocytic medullary reticulosis. Lancet 1939; 234: 194-198.
35. Akashi K, Hayashi S, Gondo H, Mizuno S, Harada M, Tamura K, Yamasaki K, Shibuya T, Uike N, Okamura T, et al: Involvement of interferon-gamma and macrophage colonystimulating factor in pathogenesis of haemophagocytic lymphohistiocytosis in adults. Br J Haematol 1994; 87: 243-250.
36. Hasegawa D, Kojima S, Tatsumi E, Hayakawa A, Kosaka Y, Nakamura H, Sako M, Osugi Y, Nagata S, Sano K: Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia. Blood 1998; 91: 2793-2799.
37. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U: Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 1991; 78: 2918-2922.
38. Rigante D, Capoluongo E, Bertoni B, Ansuini V, Chiaretti A, Piastra M, Pulitano S, Genovese O, Compagnone A, Stabile A: First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 2007; 56: 658-661.
39. Imashuku S, Hibi S, Sako M, Ishida Y, Mugishima H, Chen J, Tsunematsu Y: Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood 1995; 86: 4706-4707.
40. Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, Oda H: Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004; 50: 1935-1938.
41. Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G, Matsuda Y, Ohta H, Fujisaki H, Kobayashi M, Sakata N, Kawa-Ha K, Okada S, Tawa A: Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 1997; 89: 4100-4103.
42. Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C: Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 2005; 105: 1648-1651.
43. Kelly A, Ramanan AV: A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 2008; 4: 615-620.
44. Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED: Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 2006; 148: 683-686.
45. Schaer DJ, Schleiffenbaum B, Kurrer M, Imhof A, Bachli E, Fehr J, Moller HJ, Moestrup SK, Schaffner A: Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol 2005; 74: 6-10.
46. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G: Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005; 142: 481-489.
47. Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb BS, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA: Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007; 56: 3793-3804.
48. Egeler RM, Shapiro R, Loechelt B, Filipovich A: Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 1996; 18: 340-345.
49. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G, Kumar V: Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957-1959.
50. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, Grom AA: Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7:R30-R37.
51. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W: Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) 2003; 42: 375-379.
52. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, Binstadt BA: Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 567-570.
53. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA: Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 2008; 58: 2892-2896.
54. Grom AA: Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 2004; 50: 689-698.
55. Stepp SE, Mathew PA, Bennett M, de Saint Basile G, Kumar V: Perforin: more than just an effector molecule. Immunol Today 2000; 21: 254-256.
56. Cortis E, Insalaco A: Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl 2006; 95: 38-41.
57. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM: Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 2001; 40: 1285-1292.
58. Hewagama A, Richardson B: The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33: 3-11.
59. Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, Meroni PL, Cugno M: Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-179.
60. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, Mc-Clain K, Webb D, Winiarski J, Janka G: HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124-131.
61. Coca A, Bundy KW, Marston B, Huggins J, Looney RJ: Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol 2009; 132: 10-18.
62. Vital EM, Emery P: The development of targeted therapies in rheumatoid arthritis. J Autoimmun 2008; 31: 219-227.
63. Sanchez-Pernaute O, Ospelt C, Neidhart M, Gay S: Epigenetic clues to rheumatoid arthritis. J Autoimmun 2008; 30: 12-20.
64. Pauley KM, Cha S, Chan EK: MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009; 32: 189-194.
65. Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G: Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 2002; 100: 2367-2373.
66. Imashuku S, Kuriyama K, Sakai R, Nakao Y, Masuda S, Yasuda N, Kawano F, Yakushijin K, Miyagawa A, Nakao T, Teramura T, Tabata Y, Morimoto A, Hibi S: Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol 2003; 41: 103-109.
67. Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Hibi S: Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 2665-2673.
68. Janka GE, Schneider EM: Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 2004; 124: 4-14.
69. Takahashi N, Chubachi A, Kume M, Hatano Y, Komatsuda A, Kawabata Y, Yanagiya N, Ichikawa Y, Miura AB, Miura I: A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol 2001; 74: 209-213.
70. Tsuda H: Hemophagocytic syndrome (HPS) in children and adults. Int J Hematol 1997; 65: 215-226.
71. Imashuku S, Teramura T, Morimoto A, Hibi S: Recent developments in the management of haemophagocytic lymphohistiocytosis. Expert Opin Pharmacother 2001; 2: 1437-1448.
72. Kaito K, Kobayashi M, Katayama T, Otsubo H, Ogasawara Y, Sekita T, Saeki A, Sakamoto M, Nishiwaki K, Masuoka H, Shimada T, Yoshida M, Hosoya T: Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 1997; 59: 247-253.
73. Kumar MK, Suresh MK, Dalus D: Macrophage activation syndrome. J Assoc Physicians India 2006; 54: 238-240.
74. Lurati A, Terruzi B, Salmaso A, Demarco G, Pontikaki I, Gattinara M, Gerloni V, Fantini F: Macrophage activation syndrome (MAS) during anti-IL1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis (SOJIA): a report and review of the literature. Pediatr Rheumatol Online J 2005 3: 79-85.
75. Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, Spaeth PJ, Neftel KA: Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol 2001; 68: 4-10.
76. Burt RK, Testori A, Craig R, Cohen B, Suffit R, Barr W: Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned? J Autoimmun 2008; 30: 116-120.
77. Eisenberg R: Why can't we find a new treatment for SLE? J Autoimmun 2009; 32: 223-230.
78. Marmont AM: Will hematopoietic stem cell transplantation cure human autoimmune diseases? J Autoimmun 2008; 30: 145-150.
79. Eraso R, Gedalia A, Espinoza LR: Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2002; 29: 1104, author reply 1104-1105.
80. Chen HH, Kuo HC, Wang L, Yu HR, Shen JM, Kwang KP, Yang KD: Childhood macrophage activation syndrome differs from infection-associated hemophagocytosis syndrome in etiology and outcome in Taiwan. J Microbiol Immunol Infect 2007; 40: 265-271.
81. Imashuku S, Ueda I, Teramura T, Mori K, Morimoto A, Sako M, Ishii E: Occurrence of haemophagocytic lymphohistiocytosis at less than 1 year of age: analysis of 96 patients. Eur J Pediatr 2005; 164: 315-319.
82. Kuzmanova SI: The macrophage activation syndrome: a new entity, a potentially fatal complication of rheumatic disorders. Folia Med (Plovdiv) 2005; 47: 21-25.
83. Ozawa K, Sato K, Oh I, Ozaki K, Uchibori R, Obara Y, Kikuchi Y, Ito T, Okada T, Urabe M, Mizukami H, Kume A: Cell and gene therapy using mesenchymal stem cells (MSCS). J Autoimmun 2008; 30: 121-127.
84. Invernizzi P: Future directions in genetic for autoimmune diseases. J Autoimmun 2009; 33: 1-2.
85. Kobayashi I, Yamada M, Kawamura N, Kobayashi R, Okano M, Kobayashi K: Plateletspecific hemophagocytosis in a patient with juvenile dermatomyositis. Acta Paediatr 2000; 89: 617-619.
86. Kaneko K, Takahashi K, Fujiwara S, Maruyama T, Obinata K: Kawasaki disease followed by haemophagocytic syndrome. Eur J Pediatr 1998; 157: 610-611.
87. Muise A, Tallett SE, Silverman ED: Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003; 112:e495.
88. Javier RM, Sibilia J, Offner C, Albert A, Kuntz JL: Macrophage activation syndrome in lupus (in French). Rev Rhum Ed Fr 1993; 60: 831-835.
89. McCann LJ, Hasson N, Pilkington CA: Macrophage activation syndrome as an early presentation of lupus. J Rheumatol 2006; 33: 438-440.
90. Takahashi K, Kumakura S, Ishikura H, Murakawa Y, Yamauchi Y, Kobayashi S: Reactive hemophagocytosis in systemic lupus erythematosus. Intern Med 1998; 37: 550-553.
91. Tsuji T, Ohno S, Ishigatsubo Y: Liver manifestations in systemic lupus erythematosus: high incidence of hemophagocytic syndrome. J Rheumatol 2002; 29: 1576-1577.
92. Wong KF, Hui PK, Chan JK, Chan YW, Ha SY: The acute lupus hemophagocytic syndrome. Ann Intern Med 1991; 114: 387-390.
93. Pamuk ON, Pamuk GE, Usta U, Cakir N: Hemophagocytic syndrome in one patient with adult-onset Still's disease. Presentation with febrile neutropenia. Clin Rheumatol 2007; 26: 797-800.
94. Lou YJ, Jin J, Mai WY: Ankylosing spondylitis presenting with macrophage activation syndrome. Clin Rheumatol 2007; 26: 1929-1930.
95. Reiner AP, Spivak JL: Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore) 1988; 67: 369-388.
96. Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B: Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease. Presse Med 2005; 34: 583-584.
97. James DG, Stone CD, Wang HLL, Stenson WF: Reactive hemphagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 573-580.
98. Davies SV, Dean JD, Wardrop CA, Jones JH: Epstein-Barr virus-associated haemophagocytic syndrome in a patient with juvenile chronic arthritis. Br J Rheumatol 1994; 33: 495-497.
99. de Benedetti F, Pignatti P, Massa M, Sartirana P, Ravelli A, Cassani G, Corti A, Martini A: Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br J Rheumatol 1997; 36: 581-588.
100. Fishman D, Rooney M, Woo P: Successful management of reactive haemophagocytic syndrome in systemic-onset juvenile chronic arthritis. Br J Rheumatol 1995; 34: 888.
101. Gianella S, Schaer DJ, Schwarz U, Kurrer M, Heppner FL, Fehr J, Seebach JD: Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still's disease and concurrent macrophage activation syndrome. Am J Hematol 2008; 83: 424-427.
102. Grom AA, Passo M: Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996; 129: 630-632.
103. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM: Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 750-754.
104. Prieur AM, Stephan JL: Macrophage activation syndrome in rheumatic diseases in children (in French). Rev Rhum Ed Fr 1994; 61: 447-451.
105. Ravelli A, De Benedetti F, Viola S, Martini A: Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 1996; 128: 275-278.
106. Stern A, Riley R, Buckley L: Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol 2001; 7: 252-256.
107. Tapia Ceballos L, Picazo Angelin B, Romero Sanchez J, Diaz Cabrera R, Romero Narbona F, Romero Gonzalez J: Macrophage activation syndrome secondary to Still disease (in Spanish). An Esp Pediatr 1999; 51: 194-196.
108. Tristano AG: Macrophage activation syndrome associated with systemic onset juvenile rheumatoid arthritis. South Med J 2006; 99: 786-787.
109. Tristano AG, Casanova-Escalona L, Torres A, Rodriguez MA: Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy. J Clin Rheumatol 2003; 9: 253-258.
110. Horne A, Ramme KG, Rudd E, Zheng C, Wali Y, al-Lamki Z, Gurgey A, Yalman N, Nordenskjold M, Henter JI: Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol 2008; 143: 75-83.
111. Rudd E, Bryceson YT, Zheng C, Edner J, Wood SM, Ramme K, Gavhed S, Gurgey A, Hellebostad M, Bechensteen AG, Ljunggren HG, Fadeel B, Nordenskjold M, Henter JI: Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis. J Med Genet 2008; 45: 134-141.
112. Mehdizadeh M, Zamani G: Griscelli syndrome: a case report. Pediatr Hematol Oncol 2007; 24: 525-529.
113. Andre N, Roquelaure B, Caillez M, Chrestian M, Moncla A, Blanco-Betancourt C, Schiff C: Macrophage activation syndrome mimicking life-threatening infection in a patient with variable immunodeficiency, centromeric instability, and facial anomalies. Pediatrics 2004; 114: 1127.
114. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG: Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
115. Rubin CM, Burke BA, McKenna RW, Mc-Clain KL, White JG, Nesbit ME Jr, Filipovich AH: The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 1985; 56: 524-530.
116. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, Kontny U, Muller C, Nurden A, Rohr J, Henschen M, Pannicke U, Niemeyer C, Nurden P, Ehl S: Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 2006; 108: 81-87.
117. Silverman ED, Miller JJ 3rd, Bernstein B, Shafai T: Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103: 872-876.
118. Jacobs JC, Gorin LJ, Hanissian AS, Simon JL, Smithwick EM, Sullivan D: Consumption coagulopathy after gold therapy for JRA. J Pediatr 1984; 105: 674-675.
119. Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A: Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2001; 28: 865-867.
120. Sterba G, Rodriguez C, Sifontes S, Vigilanza P: Macrophage activation syndrome due to methotrexate in a 12-year-old boy with dermatomyositis. J Rheumatol 2004; 31: 1014-1015, author reply 1015.
121. Barash J, Cooper M, Tauber Z: Hepatic, cutaneous and hematologic manifestations in juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 541-543.
122. Olgar S, Ertugrul T, Devecioglu O, Nisli K, Omeroglu RE: Does red-man reaction stimulate macrophage activation syndrome in children with systemic juvenile idiopathic arthritis? J Rheumatol 2007; 34: 2491-2494.
123. Brinkman DM, de Kleer IM, ten Cate R, van Rossum MA, Bekkering WP, Fasth A, van Tol MJ, Kuis W, Wulffraat NM, Vossen JM: Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 2007; 56: 2410-2421.
124. Sreedharan A, Bowyer S, Wallace CA, Robertson MJ, Schmidt K, Woolfrey AE, Nelson RP Jr: Macrophage activation syndrome and other systemic inflammatory conditions after BMT. Bone Marrow Transplant 2006; 37: 629-634.
125. ten Cate R, Brinkman DM, van Rossum MA, Lankester AC, Bredius RG, Egeler MR, van Tol MJ, Vossen JM: Macrophage activation syndrome after autologous stem cell transplantation for systemic juvenile idiopathic arthritis. Eur J Pediatr 2002; 161: 686-686
126. Goulet O, Girot R, Maier-Redelsperger M, Bougle D, Virelizier JL, Ricour C: Hematologic disorders following prolonged use of intravenous fat emulsions in children. JPEN J Parenter Enteral Nutr 1986; 10: 284-288.
127. Soult Rubio JA, Garcia Bernabeu V, Sanchez Alvarez MJ, Munoz Saez M, Lopez Castilla JD, Tovaruela Santos A: Macrophage activation syndrome: a diagnostic challenge (in Spanish). An Esp Pediatr 2002; 56: 165-167.
128. Lecointe D, Fabre M, Habes D, Mielot F, Bernard O, Nordmann P: Macrophage activation syndrome in primary human herpes virus -6 infection: a rare condition after liver transplantation in infants (in French). Gastroenterol Clin Biol 2000; 24: 1227-1228.
129. Russo RA, Rosenzweig SD, Katsicas MM: Hepatitis A-associated macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: report of 2 cases. J Rheumatol 2008; 35: 166-168.
130. Seidel MG, Kastner U, Minkov M, Gadner H: IVIG treatment of adenovirus infectionassociated macrophage activation syndrome in a two-year-old boy: case report and review of the literature. Pediatr Hematol Oncol 2003; 20: 445-451.
131. Francois B, Clavel M, Trimoreau F, Desachy A, Slaouti P, Gastinne H: Pancytopenia and pulmonary tuberculosis. Significance of a hemophagocytic syndrome (in French). Rev Mal Respir 1998; 15: 668-670.
132. Gagnaire MH, Galambrun C, Stephan JL: Hemophagocytic syndrome: a misleading complication of visceral leishmaniasis in children - a series of 12 cases. Pediatrics 2000; 106:E58.
133. Algayres JP, Daly JP, Oddes B, Valmary J, Halna du Fretay X, Maurel C, Thomas A, Chabierski M, Larroque P, Laverdant C: Hepatic manifestations in Still's disease (in French). Ann Med Interne (Paris) 1988; 139: 476-481.
134. Balduck N, Otten J, Verbruggen L, Bougatef A, Ramet J, Piepsz A: Sudden death of a child with juvenile chronic arthritis, probably due to indomethacin. Eur J Pediatr 1987; 146: 620.
135. Bray VJ, Singleton JD: Disseminated intravascular coagulation in Still's disease. Semin Arthritis Rheum 1994; 24: 222-229.
136. Cuende E, Vesga JC, Perez LB, Ardanaz MT, Guinea J: Macrophage activation syndrome as the initial manifestation of systemic onset juvenile idiopathic arthritis. Clin Exp Rheumatol 2001; 19: 764-765.
137. Heaton DC, Moller PW: Still's disease associated with Coxsackie infection and haemophagocytic syndrome. Ann Rheum Dis 1985; 44: 341-344.
138. Hertzberger-ten Cate R, Cats A: Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 85-88.
139. Kornreich H, Malouf NN, Hanson V: Acute hepatic dysfunction in juvenile rheumatoid arthritis. J Pediatr 1971; 79: 27-35.
140. Makela AL, Lang H, Korpela P: Toxic encephalopathy with hyperammonaemia during high-dose salicylate therapy. Acta Neurol Scand 1980; 61: 146-156.
141. Morris JA, Adamson AR, Holt PJ, Davson J: Still's disease and the virus-associated haemophagocytic syndrome. Ann Rheum Dis 1985; 44: 349-353.
142. Pinedo HM, van de Putte LB, Loeliger EA: Salicylate-induced consumption coagulopathy. Ann Rheum Dis 1973; 32: 66-68.
143. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA: Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001; 28: 2120-2124.
144. Rich RR, Johnson JS: Salicylate hepatotoxicity in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1973; 16: 1-9.
145. Sbarbaro JA, Bennett RM: Aspirin hepatotoxicity and disseminated intravascular coagulation. Ann Intern Med 1977; 86: 183-185.
146. Ulshen MH, Grand RJ, Crain JD, Gelfand EW: Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis. J Pediatr 1978; 93: 1034-1037.
147. You CR, Kim HR, Yoon CH, Lee SH, Park SH, Kim HY: Macrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: a case report. J Korean Med Sci 2006; 21: 1124-1127.
148. Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D: HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med Pediatr Oncol 1997; 28: 342-347.
149. Matsumoto Y, Naniwa D, Banno S, Sugiura Y: The efficacy of therapeutic plasmapheresis for the treatment of fatal hemophagocytic syndrome: two case reports. Ther Apher 1998; 2: 300-304.
150. Prendiville JS, Tucker LB, Cabral DA, Crawford RI: A pruritic linear urticarial rash, fever, and systemic inflammatory disease in five adolescents: adult-onset Still disease or systemic juvenile idiopathic arthritis sine arthritis? Pediatr Dermatol 2004; 21: 580-588.
151. Sproat LO, Pantanowitz L, Lu CM, Dezube BJ: Human immunodeficiency virus-associated hemophagocytosis with iron-deficiency anemia and massive splenomegaly. Clin Infect Dis 2003; 37:e170-e173.